🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 16 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 05/01/2023 | 284,33 | 290,17 | 283,90 | 287,89 | +0,37% | 2,21% | 1.187.000 |
| 04/01/2023 | 288,30 | 289,29 | 283,98 | 286,83 | +0,28% | 1,84% | 1.137.400 |
| 03/01/2023 | 288,61 | 289,06 | 283,50 | 286,02 | -0,96% | 1,93% | 1.100.400 |
| 30/12/2022 | 288,67 | 289,32 | 284,40 | 288,78 | -0,10% | 1,70% | 1.030.700 |
| 29/12/2022 | 287,22 | 291,73 | 285,80 | 289,08 | +1,16% | 2,06% | 894.800 |
| 28/12/2022 | 287,00 | 289,68 | 284,76 | 285,76 | -0,54% | 1,71% | 842.500 |
| 27/12/2022 | 290,00 | 291,00 | 285,99 | 287,32 | -0,82% | 1,73% | 671.100 |
| 23/12/2022 | 292,80 | 294,82 | 288,07 | 289,69 | -1,44% | 2,31% | 701.100 |
| 22/12/2022 | 290,19 | 294,34 | 288,19 | 293,92 | +1,16% | 2,12% | 1.189.200 |
| 21/12/2022 | 292,26 | 294,39 | 289,28 | 290,55 | -0,91% | 1,75% | 1.539.400 |
| 20/12/2022 | 291,80 | 296,00 | 291,30 | 293,23 | +0,56% | 1,61% | 1.287.700 |
| 19/12/2022 | 301,55 | 302,59 | 289,48 | 291,59 | -4,33% | 4,35% | 1.658.200 |
| 16/12/2022 | 305,46 | 307,66 | 302,85 | 304,80 | -1,17% | 1,57% | 3.091.400 |
| 15/12/2022 | 311,23 | 312,40 | 307,14 | 308,40 | -1,18% | 1,69% | 1.008.900 |
| 14/12/2022 | 305,86 | 314,80 | 304,52 | 312,09 | +1,63% | 3,36% | 1.402.500 |
| 13/12/2022 | 317,00 | 317,33 | 306,77 | 307,09 | -2,26% | 3,33% | 2.006.200 |
| 12/12/2022 | 315,22 | 315,41 | 311,14 | 314,19 | +0,63% | 1,35% | 1.401.800 |
| 09/12/2022 | 319,30 | 321,15 | 311,79 | 312,22 | -2,83% | 2,93% | 1.007.700 |
| 08/12/2022 | 317,55 | 324,75 | 316,95 | 321,32 | +1,18% | 2,46% | 1.147.900 |
| 07/12/2022 | 311,81 | 317,71 | 310,65 | 317,58 | +1,85% | 2,26% | 871.200 |
| 06/12/2022 | 316,44 | 317,28 | 310,04 | 311,81 | -1,82% | 2,29% | 1.064.400 |
| 05/12/2022 | 318,85 | 319,69 | 315,55 | 317,60 | -1,17% | 1,30% | 812.900 |
| 02/12/2022 | 317,40 | 322,45 | 316,88 | 321,37 | +0,19% | 1,75% | 1.094.800 |
| 01/12/2022 | 318,55 | 321,52 | 315,18 | 320,76 | +1,38% | 1,99% | 1.549.100 |
| 30/11/2022 | 319,52 | 322,74 | 314,03 | 316,40 | +0,02% | 2,73% | 6.633.400 |
| 29/11/2022 | 315,69 | 317,21 | 312,47 | 316,33 | +0,33% | 1,50% | 1.380.400 |
| 28/11/2022 | 313,78 | 320,93 | 313,51 | 315,30 | +0,74% | 2,36% | 1.113.500 |
| 25/11/2022 | 315,17 | 317,03 | 312,01 | 312,98 | -1,01% | 1,59% | 713.700 |
| 23/11/2022 | 323,48 | 323,61 | 315,28 | 316,16 | -1,65% | 2,58% | 1.042.800 |
| 22/11/2022 | 317,83 | 322,26 | 313,06 | 321,48 | +1,67% | 2,89% | 1.461.100 |